February 28, 2022 02:14 PM EST
R&D

Sanofi, Re­gen­eron build their case for yet an­oth­er ap­proval for im­munol­o­gy star Dupix­ent

John Carroll

Editor & Founder

Over the week­end Sanofi and Re­gen­eron post­ed an­oth­er up­beat round of da­ta from their Phase III pro­gram for the pow­er­house Dupix­ent — this time in eosinophilic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times